Author: Nichols Martin|| Date Published: July 31, 2020
Pharmaceutical company GlaxoSmithKline has been awarded a $342M contract by the U.S. Army to obtain COVID-19 vaccines in mass quantities from multiple vendors.
The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.
Army Contracting Command received one bid for the procurement.
Contract work will take place at Research Triangle Park in North Carolina through Feb. 28, 2021.
Shield AI has agreed to acquire simulation software company Aechelon Technology as part of efforts to expand its technological capabilities. The San Diego-based…
SentinelOne, a company specializing in artificial intelligence security, has promoted Barry Padgett to president and chief operating officer. The appointment takes effect…
Anduril Industries and Palantir Technologies are helping develop software for the potential $185 billion Golden Dome next-generation missile defense shield,…
